Anti-Anaplastic Lymphoma Kinase Antibody, Non-Fucosylated (19C10) (CAT#: BioBet-552ZP) Datasheet

ALK

anaplastic lymphoma receptor tyrosine kinase

Plasma membrane

Diseases associated with ALK include Neuroblastoma 3 and Neuroblastoma.

Its related pathways are Activation of cAMP-Dependent PKA and Actin Nucleation by ARP-WASP Complex.

Neuronal receptor tyrosine kinases are essentially and transiently expressed in specific areas of the central and peripheral nervous systems, and play an important role in the development and differentiation of the nervous system. By specifically activating the mitogen-activated protein kinase (MAPK) pathway, signals are transmitted from the ligand on the cell surface. Almost only the first tyrosine of the Y-x-x-x-Y-Y motif is phosphorylated. With the activation of the ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as MAPK1/ERK2 and MAPK3/ERK1. As a receptor for secreting growth factor ligand polyiodine factor (PTN) and a PTN-related factor midkine (MDK), it participates in PTN and MDK signal transduction. PTN binding can induce the activation of MAPK pathway, which is of great significance for PTN anti-apoptotic signal and regulation of cell proliferation. mdk binding induces the phosphorylation of ALK's target insulin receptor substrate (IRS1), activating mitogen-activated protein kinases (MAPKs) and pi3-kinase, leading to induction of cell proliferation. It is possible to activate nf-kpa-b through IRS1 and AKT serine/threonine kinase. Recruiting IRS1 to activate ALK and activation of nf-kpa-b are critical to the autocrine growth and survival signals of MDK.

Cancer antibody; Controls and Markers antibody; Neuroscience antibody

Phosphorylated at tyrosine residues by autocatalysis, which activates kinase activity. In cells not stimulated by a ligand, receptor protein tyrosine phosphatase beta and zeta complex (PTPRB/PTPRZ1) dephosphorylates ALK at the sites in ALK that are undergoing autophosphorylation through autoactivation. Phosphorylation at Tyr-1507 is critical for SHC1 association. N-glycosylated.

Protein Based Therapies
Monoclonal antibody (mAb)

IgM

19C10

Mouse

Human

ADCC-Enhanced anti-Anaplastic Lymphoma Kinase (19C10) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.

Cancer

Cancer